Company Overview and News
On Dec 11, we issued an updated research report on leading medical devices company Inogen Inc. (INGN - Free Report) . The stock carries a Zacks Rank #3 (Hold). (47-0)
Inogen, Inc. (NASDAQ:INGN) has 213 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 21,529,169 shares. Largest shareholders include Novo A/S, Brown Capital Management Llc, BlackRock Inc., Vanguard Group Inc, Blair William & Co/il, Dimensional Fund Advisors Lp, State Street Corp, TimesSquare Capital Management, LLC, FMR LLC / Fidelity Management & Research, and New York State Common Retirement Fund. (45-0)
Good afternoon everyone and welcome to the Inogen 2017 Third Quarter Financial Results Conference Call. All participants will be in a listen-only mode. [Operator Instructions]. After today's presentation there will be an opportunity to ask questions. [Operator Instructions]. Please also note that today's event is being recorded. At this time, I'd like to turn the conference call over to Mr. Matt Bacso, Investor Relations Manager. (2-0)
After a solid third quarter of 2017, Inogen Inc. (INGN - Free Report) was recently recognized as one of the fastest growing companies in North America by Deloitte’s Technology Fast 500. (10-0)
Inogen Inc. (INGN - Free Report) reported third-quarter 2017 earnings of 33 cents per share which comfortably beat the Zacks Consensus Estimate of 29 cents and improved from the year-ago figure of 16 cents. (8-0)
This article elucidates the purpose and traits of good shareholder letters based on an analysis of all 601 companies in the S&P SmallCap Index. (321-0)
McKesson Corp. (MCK - Free Report) recently announced that it has entered into an agreement to buy RxCrossroads from CVS Health Corp. (CVS - Free Report) . RxCrossroads is a provider of tailored services to pharmaceutical and biotechnology manufacturers. The transaction is valued at $735 million. The deal will be entirely funded by cash on hand. The acquisition is expected to close in fourth-quarter 2017. (21-0)
Third-quarter releases are keeping Wall Street on its toes. Even then, uncertainty related to the Trump administration’s Obamacare repeal & replacement effort refuses to fully go away. The President’s latest executive order has added to the issues facing the industry. (74-0)
Novo A/S has disclosed 20 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 1,050,041,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Novo A/S's top holdings are Inogen, Inc. (NASDAQ:INGN) , AnaptysBio, Inc. (NASDAQ:ANAB) , Acceleron Pharma Inc. (NASDAQ:XLRN) , Spectranetics Corp. (The) (NASDAQ:SPNC) , and Dermira, Inc. (8-0)
Everyone is probably in search of earning beat this reporting cycle. Out of 350 tickers of the S&P 500 index that have reported already, 74% beat on bottom line and 68% surpassed revenue estimates, as per the Earnings Trends.
Goleta, CA-based Inogen, Inc. (INGN - Free Report) reported second-quarter 2017 earnings of 38 cents per share, up 5.6% year over year, which comfortably beat the Zacks Consensus Estimate of 28 cents and the year-ago figure of 36 cents.
Good afternoon and welcome to the Inogen 2017 Second Quarter Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions]. After today’s presentation, there will be an opportunity to ask questions. Please note, this event is being recorded.
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
Medtronic plc (MDT - Free Report) , a leading global player in medical technology, services and solutions, is set to make another encouraging move with respect to its highest-revenue-grossing Cardiovascular segment. Following the successful launch of its highly innovative and sophisticated Drug Eluting Stent (DES), Resolute Onyx in the U.S. in May 2017, Medtronic is now planning to start selling it in the high-growth Japan market from Jul 10, as per a Cardiovascular Business report released on Jul 7.
On Jul 6, we issued an updated research report on Salt Lake City, UT-based molecular diagnostics provider, Myriad Genetics, Inc. (MYGN - Free Report) . The company currently carries a Zacks Rank #3 (Hold).
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton